

HORMONE REPLACEMENT THERAPY

5 This application claims the benefit of U.S. Provisional Application No. 60/268,607, filed February 14, 2001, and U.S. Provisional Application No. 60/190,630, filed March 20, 2000.

BACKGROUND

10 This invention relates to methods and pharmaceutical compositions for providing hormone replacement therapy in perimenopausal, menopausal, and postmenopausal women through the continuous administration of combinations of conjugated estrogens and medroxyprogesterone acetate.

15 Menopause is generally defined as the last natural menstrual period and is characterized by the cessation of ovarian function, leading to the substantial diminution of circulating estrogen in the bloodstream. Menopause is usually identified, in retrospect, after 12 months of amenorrhea. It is not a sudden event, but is often preceded by a time of irregular menstrual cycles prior to eventual cessation
20 of menses. Following the cessation of menstruation, the decline in endogenous estrogen concentrations is typically rapid. There is a decrease in serum estrogens from circulating levels ranging from 40-250 pg/mL of estradiol and 40-170 pg/mL of estrone during ovulatory cycles to less than 15 pg/mL of estradiol and 30 pg/mL of estrone in postmenopausal women.

25 As these estrogens decline during the time preceding (perimenopause) and following the menopause (postmenopause), various physiological changes may result, including vulvar and vaginal atrophy causing vaginal dryness, pruritus and dyspareunia, and vasomotor instability manifested as hot flushes. Other menopausal
30 disturbances may include depression, insomnia, and nervousness. The long-term physiologic effects of postmenopausal estrogen deprivation may result in significant morbidity and mortality due to increase in the risk factors for cardiovascular disease and osteoporosis. Menopausal changes in blood lipid levels, a major component of the pathogenesis of coronary heart disease (CHD), may be precursors to increased

- 2 -

incidence of ischemic heart disease, atherosclerosis, and other cardiovascular disease. A rapid decrease in bone mass of both cortical (spine) and trabecular (hip) bone can be seen immediately after the menopause, with a total bone mass loss of 1% to 5% per year, continuing for 10 to 15 years.

5

Estrogen replacement therapy (ERT) is beneficial for symptomatic relief of hot flushes and genital atrophy and for prevention of postmenopausal osteoporosis. ERT has been recognized as an advantageous treatment for relief of vasomotor symptoms. There is no acceptable alternative to estrogen treatment for the atrophic changes in the vagina; estrogen therapy increases the vaginal mucosa and decreases vaginal dryness. Long term ERT is the key to preventing osteoporosis because it decreases bone loss, reduces spine and hip fracture, and prevents loss of height. In addition, ERT has been shown to be effective in increasing high density lipoprotein-cholesterol (HDL-C) and in reducing low density lipoprotein cholesterol (LDL-C), affording possible protection against CHD. ERT also can provide antioxidant protection against free radical mediated disorders or disease states. Estrogens have also been reported to confer neuroprotection, and inhibit neurodegenerative disorders, such as Alzheimer's disease (see U.S. Patent 5,554,601, which is hereby incorporated by reference). The following table contains a list of estrogen preparations currently available.

10

15

20

03000078-0315004

- 3 -

Estrogen replacement therapies available in the United States and/or Europe

Generic Name	Brand Name	Strength
Oral estrogens		
Conjugated equine estrogens (natural)	Premarin	0.3, 0.625, 0.9, 1.25, 2.5 mg
Conjugated estrogens (synthetic)	Cenestin	0.625, 0.9 mg
Esterified estrogens (75-80% estrone sulfate 6-15% equilin sulfate derived from plant sterols)	Estratab	0.3, 0.625, 1.25, 2.5 mg
Etopipate (Piperazine estrone sulfate)	Ogen Ortho-Est	0.625, 1.25, 2.5 mg
Micronized estradiol	Estrace	0.5, 1.0, 2.0 mg
Raloxifene (selective estrogen receptor modulator)	Evista	60 mg
Esterified estrogens and methylestosterone		
	Estratest	1.25 mg esterified estrogen and 2.5 mg methylestosterone
	Estratest HS	0.625 mg esterified estrogen and 1.25 mg methylestosterone
Estradiol valerate	Climaval	1 mg, 2 mg
Estradiol	Elleste Solo	1 mg, 2 mg
Estradiol	Estroferm	2 mg
Estradiol	Estroferm Forte	4 mg
Piperazine esterone sulfate	Harmogen	1.5 mg
Combination: Estrone Estradiol	Hormonin	1.4 mg 0.6 mg
Estradiol valerate	Progynova	0.27 mg
Estradiol	Zumenon	1 mg, 2 mg
Transdermal estrogens		
Estradiol	Alora (twice weekly)	0.025, 0.0375, 0.05, 0.075,
	Climara (weekly)	0.1 mg of estradiol released
	Estraderm (2x weekly)	daily (dose options for various
	Fem Patch (weekly)	products)
	Vivelle (twice weekly)	
Estradiol	Dermestril	25, 50, 100 µg
Estradiol	Estraderm	25, 50, 100 µg
Estradiol	Evorel (System)	25, 50, 75, 100 µg
Estradiol	Fematrix	40, 80 µg
Estradiol	Menorest	25, 37.5, 50, 75 µg
	Progynova TS	
Estradiol	And TS Forte (Climara)	50, 100 µg
Vaginal estrogens		
Conjugated equine estrogens	Premarin vaginal cream	
Dienestrol	Ortho dienestrol cream	0.625 mg/g
Estradiol	Estring	0.1 mg/g
Etopipate	Ogen vaginal cream	7.5 µg
Micronized estradiol	Estrace vaginal cream	1.5 mg/g 1.0 mg/g

5

To minimize the occurrence of estrogen-related side effects and to maximize the benefit-risk ratio, the lowest dose effective in relief of symptoms and prevention of osteoporosis should be used. Although ERT reduces the relative risk (RR) for ischemic heart disease (RR, 0.50) and osteoporosis (RR, 0.40), the relative risk of endometrial cancer for postmenopausal women with a uterus may be increased.

10

- 4 -

There are extensive clinical data showing that the relative risk of endometrial cancer can be reduced by the addition of a progestin, either sequentially or continuously. The addition of a progestin to estrogen therapy prevents estrogen-induced endometrial proliferation. Continuous combined hormone replacement therapy (HRT), with appropriate doses of daily estrogen and progestin, has been shown to be effective in relieving vaginal atrophy and vasomotor symptoms, preventing postmenopausal osteoporosis, and reducing the risk of endometrial cancer by prevention of endometrial hyperplasia. The following table contains a list of some currently available oral combination HRT products.

10

Oral Combination HRT Products

Brand Name	Estrogen/Progestin	Strengths
Activelle	Estradiol	1 mg
	Norethisterone acetate (NETA)	0.5 mg
Climagest	Estradiol valerate (Climaval)	1 or 2 mg
	Norethisterone (NET)	1 mg days 17-28
Cyclo Prognova	Estradiol valerate	1 or 2 mg, days 1-21
	Levonorgestrel	250 or 500 µg, days 2-21
Elleste Duet	Estradiol	1 or 2 mg
	Norethisterone acetate	1 mg days 17-28
Femoston	Estradiol	1 or 2 mg
	Dydrogesterone	10 or 20 mg
Kliogest	Estradiol	2 mg
	Norethisterone acetate	1 mg
Improvera	Piperazine estrone sulfate	1.5 mg
	Medroxyprogesterone acetate (MPA)	10 mg, days 17-28
Nuvelle	Estradiol valerate (Prognova)	2 mg
	Levonorgestrel	75 µg, days 17-28
Premphase	Conjugated estrogens	0.625 mg
	MPA	5.0 mg
Prempro	Conjugated estrogens	0.625 mg
	MPA	2.5 or 5.0 mg
Trisequens And Trisequens Forte	Estradiol	2 or 4 mg, days 1-22
	Norethisterone	1 mg, days 23-28
		1 mg, days 13-22
Ortho-Prefest	Estradiol	1.0 mg, days 1-6
	Nogestimate	0.09 mg, days 4-6
Femhrt 1/5	Ethinyl estradiol	1.0 mg
	Norethindrone acetate	5 µg

Since it is possible that progestins ameliorate of the favorable estrogen effects on lipids and may potentially impair of glucose tolerance, it is desirable, and an objective to find the lowest dose estrogen plus progestin HRT product, which also
5 minimizes or eliminates endometrial hyperplasia. In addition, a major factor affecting a woman's decision to start and to continue taking HRT is vaginal bleeding, and many women would prefer a bleed-free product. Therefore, another objective is to provide the lowest effective dose which provides an acceptable bleeding pattern. Doses as low as NETA 0.5 mg, NET 0.35 mg, MPA 2.5 mg, levonorgestrel 0.25 mg,
10 and dydrogesterone 5 mg have been used previously in continuous uninterrupted HRT regimens.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the mean number of hot flushes per day in patients receiving
15 PREMARIN plus MPA combinations or placebo.

FIG. 2 shows the mean severity of hot flushes in patients receiving PREMARIN plus MPA combinations or placebo.

FIG. 3 shows the percentage of patients with amenorrhea in patients receiving PREMARIN plus MPA combinations or placebo.
20

DESCRIPTION OF THE INVENTION

The purpose of this invention is to provide the significant benefits of a commercially successful HRT product, such as PREMPRO (0.625 mg conjugated equine estrogens, USP plus 2.5 mg MPA), while lowering the dosage of MPA below
25 that which has previously been demonstrated to be effective, and preferably also lowering the dosage of the conjugated estrogens. This invention provides a method of treating or inhibiting menopausal or postmenopausal disorders in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises providing to said woman, continuously and uninterruptedly over the
30 treatment period, a combination of conjugated estrogens (natural or synthetic) and a daily dosage of about 1.5 medroxyprogesterone acetate (MPA). The dosage is preferably provided as a pharmaceutical composition for use in treating menopausal or postmenopausal disorders which comprises a combination of conjugated estrogens and a dosage of about 1.5 mg MPA. This invention further provides a

- 6 -

pharmaceutical pack containing the daily dosage units of conjugated estrogen and MPA for continuous daily administration.

Conjugated estrogens refer to estrogenic steroidal substances in which one or more functional groups (typically hydroxyl groups) on the steroid exists as a conjugate (typically a sulfate or glucuronide). The conjugated estrogens may be a single conjugated estrogen, or may consist of mixtures of various conjugated estrogens. Numerous conjugated estrogens are described in the literature or are commercially available that are capable of being formulated for use in this invention either as a unitary estrogen, or may be mixed together with other synthetic and/or natural estrogens.

Conjugated estrogens may also contain other steroidal or non-steroidal compounds, which may, or may not, contribute to the overall biological effect. Such compounds include, but are not limited to, unconjugated estrogens, androstanes, and pregnanes. Preferred conjugated estrogens for use in this invention are PREMARIN (conjugated equine estrogens, USP) and CENESTIN (synthetic conjugated estrogens, A).

PREMARIN (conjugated estrogens tablets, USP) for oral administration contains a mixture of estrogens obtained exclusively from natural sources, occurring as the sodium salts of water-soluble estrogen sulfates blended to represent the average composition of material derived from pregnant mares' urine. It is a mixture of sodium estrone sulfate and sodium equilin sulfate, and at least the following 8 concomitant components, also as sodium sulfate conjugates: 17 α -dihydroequilin, 17 α -estradiol, Δ 8,9-dehydroestrone, 17 β -dihydroequilin, 17 β -estradiol, equilenin, 17 α -dihydroequilenin, and 17 β -dihydroequilenin. The make up of PREMARIN of PREMARIN is currently being analyzed, and other components are in the process of being identified and characterized. PREMARIN is indicated in the treatment of moderate to severe vasomotor symptoms associated with the menopause; treatment of vulvar and vaginal atrophy; and prevention of osteoporosis, as well as other indications approved for estrogen products.

CENESTIN (synthetic conjugated estrogens, A) tablets for oral administration contain a blend of 9 synthetic estrogenic substances: sodium estrone sulfate, sodium 17 α -dihydroequilin sulfate, sodium 17 α -estradiol sulfate, sodium equilenin sulfate, sodium 17 α -dihydroequilenin sulfate, sodium equilin sulfate, sodium 17 β -dihydroequilin sulfate, sodium 17 β -estradiol sulfate, sodium 17 α -dihydroequilenin

- 7 -

sulfate. CENESTIN is indicated in the treatment of moderate to severe vasomotor symptoms associated with the menopause.

PREMARIN, CENESTIN, and medroxyprogesterone acetate are all available from commercial sources (Wyeth-Ayerst - PREMARIN and medroxyprogesterone acetate; Duramed - CENESTIN). It is preferred that the dosage of MPA is about 1.5 mg per day. It is preferred that the conjugated estrogen constituent is PREMARIN. It is preferred that the dosage of PREMARIN is about 0.625 mg per day or less, and is more preferred that the dosage of PREMARIN is either about 0.45 mg per day or about 0.30 mg per day.

As used in accordance with this invention, the term "menopausal or postmenopausal disorder" refers to conditions, disorders, or disease states that are at least partially caused by the decreased estrogen production occurring during the perimenopausal, menopausal, or post-menopausal stages of a woman's life. Such disorders typically include, but are not limited to, one or more of, vaginal and vulvar atrophy, vasomotor instability, urinary incontinence, and increased risk of developing osteoporosis, cardiovascular disease, and diseases related to the oxidative damage from free radicals. As used herein, menopausal also includes conditions of decreased estrogen production that may be surgically, chemically, or be caused by a disease state which leads to premature diminution or cessation of ovarian function.

The term "daily" means that the dosage is to be administered at least once daily. The frequency may be preferred to be once daily, but may be more than once daily, provided that any specified daily dosage is not exceeded.

The term "combination" of conjugated estrogens and MPA means that the daily dosage of each of the components of the combination is administered during the treatment day. The components of the combination are preferably administered at the same time; either as a unitary dosage form containing both components, or as separate dosage units; the components of the combination can be administered at different times during the day, provided that the desired daily dosage is achieved.

The term "continuous and uninterrupted" means that there is no break in the treatment regimen, during the treatment period. Thus, "continuous, uninterrupted administration" of a combination, means that the combination is administered at least once daily during the entire treatment period. It is expected that the treatment period for the combination of conjugated estrogens and MPA will be for at least 30 days, preferably 120 days, and most preferably as long term treatment, and possibly

indefinite, as one of the primary reasons for administering combinations of conjugated estrogens and MPA is to treat or inhibit menopausal or postmenopausal disorders. Treatment periods also may vary depending on the symptoms to be treated. For example, for the treatment of vasomotor symptoms, it is preferred that the treatment may last from one month to several years, depending on the severity and duration of the symptoms. Physician evaluation along with patient interaction will assist the determination of the duration of treatment. For the treatment or inhibition of osteoporosis, it is preferred that the treatment period could last from six months to a number of years, or indefinitely.

This invention, also covers short term treatments or treatments of a finite term, that may be less than the 30 day preferred treatment period. It is anticipated that a patient may miss, or forget to take, one or a few dosages during the course of a treatment regimen, however, such patient is still considered to be receiving continuous, uninterrupted administration.

The term "fixed daily dosage" means that the same dosage is given every day during the treatment period. It is preferred that the MPA is given in a fixed daily dosage of about 1.5 mg, with an appropriate dose of conjugated estrogens, preferably equivalent to about 0.45 mg or about 0.30 PREMARIN. One aspect of this invention also covers situations in which a fixed daily dosage of the conjugated estrogens plus MPA combination is not given every day during the treatment period. For example, the dosage of a patient may need to be adjusted (either up or down), to achieve the desired effect during the middle of a treatment period.

The term "providing," with respect to providing a dosage of one or both of the components of this invention, means either directly administering such a component of this invention, or administering a prodrug, derivative, or analog which will form the equivalent amount of the component within the body.

It is preferred that the conjugated estrogens plus MPA combinations of this invention are provided orally. The specific dosages of conjugated estrogens plus MPA combinations of this invention that are disclosed herein are oral dosages.

The ability of the conjugated estrogens plus MPA combinations of this invention to treat or inhibit menopausal or postmenopausal disorders was confirmed in a double blind clinical study of postmenopausal women using combinations of PREMARIN plus MPA, or placebo. In this study, patients received continuous and

uninterrupted treatment for 13 cycles (1 year). The relief of vasomotor symptoms, prevention of endometrial hyperplasia, and effects on lipids, vaginal bleeding were measured throughout the study. Additionally, the effect on bone mineral density was evaluated in patients who received continuous and uninterrupted treatment for up to 26 cycles (2 years).

Vasomotor instability is a menopausal or postmenopausal disorder which is often manifested as hot flushes. In the clinical study described above, relief of vasomotor symptoms was analyzed in a subset of patients who experienced at least an average of 7-8 moderate-to-severe hot flushes per day during the 7-day period just prior to the initiation of treatment in this study. The results obtained are summarized in the tables below. The first table shows the mean number of flushes, and the second table shows the mean daily severity of the flushes. These results are also shown in FIGS. 1 and 2.

Mean Number (\pm S.E.) of Hot Flushes Per Day

Week	Placebo	Treatment Group		
		0.625 P + 2.5 M*	0.45 P + 1.5 M	0.3 P + 1.5 M
1	9.41 \pm 0.81	9.50 \pm 0.73	9.99 \pm 0.79	10.60 \pm 0.76
2	8.55 \pm 0.80	6.38 \pm 0.72	6.98 \pm 0.80	6.88 \pm 0.74
3	8.51 \pm 0.76	4.47 \pm 0.69	4.47 \pm 0.76	4.62 \pm 0.71
4	8.09 \pm 0.72	3.38 \pm 0.66	3.23 \pm 0.72	3.84 \pm 0.67
8	7.10 \pm 0.65	1.55 \pm 0.61	1.49 \pm 0.66	2.41 \pm 0.60
12	5.36 \pm 0.55	1.16 \pm 0.49	0.94 \pm 0.53	1.13 \pm 0.50

*Daily dosages of P (PREMARIN) and M (MPA).

Mean Severity (\pm S.E.) of Hot Flushes

Week	Placebo	Treatment Group		
		0.625 P + 2.5 M*	0.45 P + 1.5 M	0.3 P + 1.5 M
1	2.10 \pm 0.10	2.08 \pm 0.09	2.14 \pm 0.10	2.07 \pm 0.10
2	2.06 \pm 0.13	1.75 \pm 0.12	1.78 \pm 0.13	1.73 \pm 0.12
3	1.97 \pm 0.14	1.36 \pm 0.13	1.42 \pm 0.15	1.48 \pm 0.14
4	2.03 \pm 0.15	1.07 \pm 0.14	1.21 \pm 0.15	1.45 \pm 0.14
8	1.75 \pm 0.16	0.54 \pm 0.14	0.70 \pm 0.16	0.87 \pm 0.14
12	1.57 \pm 0.16	0.51 \pm 0.14	0.51 \pm 0.16	0.56 \pm 0.14

*Daily dosages of P (PREMARIN) and M (MPA).

As shown in both tables and Figures, all dosages of PREMARIN plus MPA reduced the number and severity of hot flushes experienced by the women in this clinical study compared with women taking placebo. All differences from placebo were significant ($p < 0.05$) by weeks 3-4. It was unexpected, however, that the lower

- 10 -

dosages of PREMARIN (0.45 and 0.3 mg) and MPA (1.5 mg), would rapidly reduce the number and severity of hot flushes to the same extent as the higher dose combination containing 0.625 mg PREMARIN plus 2.5 mg MPA.

5 Vaginal atrophy is a common menopausal or postmenopausal disorder leading to vaginal dryness, pruritus, and dyspareunia. Vaginal atrophy results from a sloughing of vaginal epithelial cells which are not replaced, leading to a thinning of the vaginal lining. The effects of the lower dose conjugated estrogen plus MPA regimens on vaginal atrophy were evaluated by comparing the vaginal maturation index of superficial cells at baseline, and after cycles 6 and 13 of treatment. The vaginal maturation index is a measure of the number of superficial vaginal epithelial cells. An increase (positive number) in the vaginal maturation index indicates a reversal (successful treatment) of vaginal atrophy. The following table summarizes the results obtained.

15

Vaginal Maturation Index for Superficial Cells - Median Change from Baseline

Treatment Group	Cycle 6	Cycle 13
0.625 P + 2.5 M*	10	10
0.45 P + 1.5 M	10	10
0.3 P + 1.5 M	10	10
Placebo	0	0

*Daily dosages of P (PREMARIN) and M (MPA).

20 These data show that all the evaluated dosages of conjugated estrogens plus MPA provided significant ($p < 0.001$) improvement in the vaginal maturation index versus placebo, demonstrating their ability to successfully treat or inhibit vaginal atrophy. It is notable that the lower dosages of conjugated estrogens plus MPA were as equally as effective as the 0.625 mg PREMARIN plus 2.5 mg MPA dosage in
25 facilitating the growth of the vaginal superficial cells.

30 As HRT using estrogens alone has been shown to increase the relative risk of endometrial hyperplasia in postmenopausal women with a uterus, the incidence of endometrial hyperplasia was evaluated in the clinical study for patients treated with PREMARIN plus MPA treated groups and placebo. Two independent pathologists evaluated endometrial biopsies in a blinded fashion. A patient was considered to have endometrial hyperplasia if both of the primary pathologists agreed on the

- 11 -

diagnosis. If they disagreed, a third pathologist was consulted, and the diagnosis of hyperplasia was based on the diagnosis of the majority. The following table summarizes the results obtained after 13 cycles of treatment.

5 Percent of Patients Developing Endometrial Hyperplasia

Treatment Group (Dosage)*	No. Hyperplasias	No. Patients/Group	Hyperplasia Rate (%)
Placebo	0	261	0.00
PREMARIN/MPA (0.625/2.5)	0	278	0.00
PREMARIN/MPA (0.45/1.5)	1	272	0.37
PREMARIN/MPA (0.3/1.5)	1	272	0.37

* All dosages are in mg/day

10 These results showed that that the use of conjugated equine estrogens/MPA at a dosage of 0.625/2.5 mg/day effectively prevented the development of endometrial hyperplasia. The results also show the unexpected result that lowering the dosage of MPA to 1.5 mg/day in PREMARIN plus MPA combinations, also continued to effectively inhibit the development of endometrial hyperplasia. The difference between the results obtained in the 1.5 mg MPA treatment groups and 2.5 mg MPA treatment groups was not statistically significant.

15 In providing an HRT regimen that will be acceptable to menopausal or postmenopausal women, it is highly desirable that the regimen produce a high rate of amenorrhea, as most of these women prefer a product which does not cause spotting or breakthrough bleeding. The following table shows the percent of women
20 experiencing amenorrheic cycles at during cycles 1, 3, 6, 9, and 13.

Percent Cycles of Amenorrhea

Cycle	Treatment Group			
	Placebo	0.625 P + 2.5 M	0.45 P + 1.5 M	0.3 P + 1.5 M
1	91.1	51.3	71.1	75.2
3	96.4	54.9	70.3	80.4
6	91.8	68.4	72.8	85.1
9	93.6	70.8	80.5	86.6
13	95.2	77.4	79.8	88.4

25 *Daily dosages of P (PREMARIN) and M (MPA).

The results show that greater than 90 percent of women receiving placebo were amenorrheic throughout the study. While the percent of amenorrheic women

- 12 -

receiving daily dosages of 0.625 mg PREMARIN plus 2.5 mg MPA is satisfactory, as measured by the commercial success of PREMPRO (0.625 mg conjugated equine estrogens plus 2.5 mg MPA), lowering the dosages of PREMARIN to either 0.45 mg or 0.3 mg and MPA to 1.5 mg, produced an equal, if not significantly better (0.3 mg PREMARIN plus 1.5 mg MPA) percent of women achieving amenorrhea, while still maintaining the other benefits of HRT. Additionally, as shown in the above table, and in FIG. 3, a higher percentage of amenorrhea was achieved more rapidly with the lower dose combinations.

It is well known that the addition of progestins to ERT regimens may ameliorate some of the beneficial cardioprotective effects conferred by the estrogen, or even produce deleterious effects on the lipid levels. In this study total cholesterol (TC), HDL, HDL₂, and LDL levels were measured. There was a general dose-response trend between treatment groups, that showed more favorable lipid profiles with higher doses of PREMARIN and lower doses of MPA. Patients receiving 0.625 mg PREMARIN + 2.5 mg MPA had slight reductions in TC, significant increases in HDL and HDL₂, and significant decreases in levels of LDL. The 0.45 mg PREMARIN plus 1.5 mg MPA dosage produced a similar favorable profile (but of less magnitude) to 0.625 mg PREMARIN + 2.5 mg MPA treated women. Women treated with 0.3 mg PREMARIN plus 1.5 mg MPA had a less favorable lipid profile (TC, HDL, HDL₂ and LDL), than women treated, with 0.625 mg PREMARIN plus 2.5 mg MPA, however, this profile was still better than those receiving placebo.

During the study, adverse events were recorded and analyzed. Treatment emergent adverse events were consistent with those seen with hormone therapy. With the exception of breast pain, the side effect profile was comparable between the PREMARIN plus MPA treatment groups. Women receiving the daily dosage of 0.3 mg PREMARIN plus 1.5 mg MPA experienced significantly less breast pain than the women taking 0.625 mg PREMARIN plus 2.5 mg MPA.

In summary the results of the clinical study demonstrated that conjugated estrogen HRT regimens containing dosages of 1.5 mg/day of MPA were equally effective in treating menopausal or postmenopausal disorders as the regimens containing the higher dose of 2.5 mg MPA (0.625 mg PREMARIN plus 2.5 mg MPA, in particular). Higher rates of amenorrhea were also achieved more rapidly..

Additionally, less breast tenderness was observed in women taking 0.3 mg PREMARIN plus 1.5 mg MPA, than in women taking the commercially available 0.625 mg PREMARIN plus 2.5 mg MPA combination.

5 It is well known that a rapid decrease in bone mass of both cortical (spine) and trabecular (hip) bone can be seen immediately after the menopause, with a total bone mass loss of 1% to 5% per year, continuing for 10 to 15 years. In the clinical study described above, bone mineral density (BMD) was determined using dual energy x-ray absorptiometry (DEXA) measurements of the lumbar spine (L2-L4),
10 femoral neck, trochanter, and total body. BMD measurements were made at least twice pre-study (7-14 days apart but not to exceed 3 weeks), during cycles 6, 13, 19, and twice during cycle 26 (7-14 days apart but not to exceed 3 weeks). The final visit results (cycle 26) are summarized in the table below.

15

Percent BMD Change (\pm S.E.) From Baseline at Final Visit

Treatment Group	Lumbar Spine	Femoral Neck	Trochanter	Total Body
Placebo	$-2.63 \pm 0.37^+$	$-1.97 \pm 0.46^+$	0.82 ± 0.58	$-1.56 \pm 0.17^+$
0.625 P + 2.5 M*	$3.77 \pm 0.37^{+, \#}$	$1.67 \pm 0.46^{+, \#}$	$4.05 \pm 0.59^{+, \#}$	$0.96 \pm 0.18^{+, \#}$
0.45 P + 1.5 M	$2.45 \pm 0.37^{+, \#}$	$1.43 \pm 0.47^{+, \#}$	$3.60 \pm 0.59^{+, \#}$	$0.56 \pm 0.18^{+, \#}$
0.3 P + 1.5 M	$1.77 \pm 0.36^{+, \#}$	$1.51 \pm 0.44^{+, \#}$	$4.66 \pm 0.56^{+, \#}$	$0.55 \pm 0.17^{+, \#}$

* Daily dosages of P (PREMARIN) and M (MPA).

+ Statistically significant ($p < 0.001$) change from baseline.

20 ++ Statistically significant ($p = 0.004$) change from baseline.

Statistically significant ($p < 0.001$) difference from placebo.

The results showed that all dosages of PREMARIN plus MPA significantly increased the BMD versus baseline and placebo in the lumbar spine, femoral neck,
25 trochanter, and total body demonstrating that combinations of conjugated estrogens plus MPA inhibited or retarded bone demineralization. These data also show that combinations of conjugated estrogens plus MPA actually increased the bone mineral density relative to pre-study baseline levels, and also relative to patients receiving placebo.

30

Based on the results observed in the clinical study described above, it has been found that the continuous and uninterrupted administration of a combination

- 14 -

conjugated estrogens plus a dosage of about mg per of medroxyprogesterone acetate is useful in treating or inhibiting menopausal or postmenopausal disorders in perimenopausal, menopausal, or postmenopausal women. More particularly, the combinations described herein are useful in treating or inhibiting vaginal or vulvar atrophy; atrophic vaginitis; vaginal dryness; pruritus; dyspareunia; dysuria; frequent urination; urinary incontinence; urinary tract infections; vasomotor symptoms, including hot flushes, myalgia, arthralgia, insomnia, irritability, and the like; inhibiting or retarding bone demineralization; increasing bone mineral density; and treating or inhibiting osteoporosis.

- 10 The combinations of this invention also exert a cardioprotective effect in perimenopausal, menopausal, and postmenopausal women, and are therefore useful in lowering cholesterol, triglycerides, Lp(a), and LDL levels; inhibiting or treating hypercholesteremia; hyperlipidemia; cardiovascular disease; atherosclerosis; peripheral vascular disease; restenosis, and vasospasm; and inhibiting vascular wall damage from cellular events leading toward immune mediated vascular damage.

- 15 The combinations of this invention are antioxidants, and are therefore useful in inhibiting disorders or disease states which involve free radicals. More particularly, the combinations of this invention are useful in treating or inhibiting free radical involvement in the development of cancers, central nervous system disorders, Alzheimer's disease, bone disease, aging, inflammatory disorders, peripheral vascular disease, rheumatoid arthritis, autoimmune diseases, respiratory distress, emphysema, prevention of reperfusion injury, viral hepatitis, chronic active hepatitis, tuberculosis, psoriasis, systemic lupus erythematosus, amyotrophic lateral sclerosis, aging effects, adult respiratory distress syndrome, central nervous system trauma and stroke, or injury during reperfusion procedures.

- 25 The combinations of this invention are useful in treating or inhibiting dementias, neurodegenerative disorders, and Alzheimer's disease; providing neuroprotection or cognition enhancement.

- 30 The conjugated estrogens and medroxyprogesterone acetate described in this invention can be either formulated as separate tablets or as a unitary combination tablet.

Either of the components or the combination may be formulated neat or may be combined with one or more pharmaceutically acceptable carriers for

administration. For example, solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.

The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.

Conjugated estrogens and MPA can be formulated in a number of ways to provide a single combination dosage form. Conjugated estrogens can be incorporated within the core of a compressed tablet and the progestin can be placed in an overcoating consisting of a compressed, film or sugar coat, as described in U.S. Patent 5,547,948, which is hereby incorporated by reference. The tablets described in U.S. Patent 5,547,948 are suitable for formulation of the conjugated estrogens and MPA described in this invention as a unitary tablet. U.S. Patent 5,908,638, which is hereby incorporated by reference, also describes combination tablets which are suitable for formulation of the conjugated estrogens and MPA described in this invention as a unitary tablet.

Conjugated estrogens may be formulated in a core containing the conjugated estrogens, and several components including alcohol, hydroxypropyl methyl cellulose, lactose monohydrate, magnesium stearate, and starch. The core can be covered with a coating made from components such as ethylcellulose, and triethyl citrate.

Both components can be incorporated in the compressed tablet core or in a tablet coating formulated to maintain drug stability and provide adequate oral bioavailability. For example, the progestin can be micronized.

Conjugated estrogens can be incorporated in granules, spheroids or other multiparticulate forms, and, if necessary, coated to provide adequate stability. These multiparticulates can be combined, in the appropriate proportions, with a powder

- 16 -

blend, granulation or multiparticulates containing the progestin and incorporated into hard gelatin capsules.

- 5 This invention also provides a pharmaceutical does pack, containing any number of daily pharmaceutical dosage units. Preferably, and conventionally, the pack contains 28 tablets or multiples thereof. The pack should indicate that the dosage units are to be taken consecutively on a daily basis until the treatment period has ended, or until the pack has been completed. The next pack should be started on the next consecutive day. For combinations containing a unitary dosage tablet
- 10 containing both conjugated estrogens and MPA, it is preferable that the pack contain one tablet corresponding to each day of administration. For combinations containing separate dosage units of conjugated estrogens and MPA, it is preferable that each one tablet of each correspond to each given day's administration, as indicated on the pill pack.

05060870:071504